StockPriceToday
Arbutus Biopharma Corporation (ABUS)
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation operates as a clinical-stage biotechnology company dedicated to developing innovative therapies for chronic hepatitis B virus (HBV) infection. The company's specialized focus on HBV treatment makes ABUS stock price particularly sensitive to clinical trial results and developments in hepatitis B therapy.
The company's research pipeline includes novel approaches to achieving functional cures for chronic HBV infection, addressing a significant global health challenge affecting millions of patients worldwide. ABUS's drug development programs target different aspects of the HBV lifecycle, including viral replication, immune system activation, and viral antigen reduction.
Investors tracking ABUS stock price monitor the company's progress through clinical development, as successful hepatitis B treatments represent substantial commercial opportunities given the large global patient population and limited current treatment options for achieving functional cures.
Arbutus Biopharma's intellectual property portfolio includes important patents related to lipid nanoparticle technology used in various drug delivery applications. The company's licensing agreements and partnerships provide additional revenue streams that support business operations and influence ABUS stock price stability while advancing its hepatitis B therapeutic programs.
ABUS Stock 12 Month Chart
Latest News for ABUS
For the quarter ended September 30, 2026, the Company’s net income was $59.1 million, or net income of $0.30 per basic and diluted common share, as compared to a net loss of $7.7 million, or a net ...
WARMINSTER, Pa. (AP) — WARMINSTER, Pa. (AP) — Arbutus Biopharma Corp. (ABUS) on Tuesday reported third-quarter net income of $59.1 million, after reporting a loss in the same period a year earlier.
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS’ in-house assets, I think Imdusiran has shown durable viral control. The main caveat ...
Other Popular Stocks
IDEXX Laboratories Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets...
Park-Ohio Holdings Corp. (PKOH) is a diversified international company providing supply chain management services and manufacturing solutions across three segments: Supply Technologies, Assembly Components,...
Bicycle Therapeutics plc is a biotechnology company developing bicycle peptide therapeutics for cancer and other diseases.